Gilead’s lenacapavir holds greater potential in reducing HIV incidence than currently marketed drugs: GlobalData - Healthcare News
Kort samengevat
Agencies such as the FDA are likely to receive regulatory submissions for lenacapavir as PrEP within the next year.
Verder lezen bij de bron
Bekijk het volledige nieuwsbericht rechtstreeks bij Financialexpress.
Lees het volledige bericht ↗